Natural history of MELAS associated with mitochondrial DNA m.3243A>G genotype.

TitleNatural history of MELAS associated with mitochondrial DNA m.3243A>G genotype.
Publication TypeJournal Article
Year of Publication2011
AuthorsKaufmann P, Engelstad K, Wei Y, Kulikova R, Oskoui M, Sproule DM, Battista V, Koenigsberger DY, Pascual JM, Shanske S, Sano M, Mao X, Hirano M, Shungu DC, DiMauro S, De Vivo DC
JournalNeurology
Volume77
Issue22
Pagination1965-71
Date Published2011 Nov 29
ISSN1526-632X
KeywordsAdolescent, Adult, Child, Child, Preschool, Cohort Studies, DNA, Mitochondrial, Female, Genetic Predisposition to Disease, Humans, Male, MELAS Syndrome, Middle Aged, Point Mutation, Prospective Studies, Young Adult
Abstract

OBJECTIVE: To describe the natural history of clinical and laboratory features associated with the m.3243A>G mitochondrial DNA point mutation. Natural history data are needed to obtain prognostic information and for clinical trial planning.

METHODS: We included 85 matrilineal relatives from 35 families with at least 2 visits in this prospective cohort study. Thirty-one were fully symptomatic with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), and 54 were carrier relatives. Evaluations included standardized questionnaires (medical history and daily living functioning), physical examination, neuropsychological testing, and a battery of imaging and laboratory tests. We evaluated changes in clinical and laboratory features over time and survival. Outcomes are reported over a follow-up period of up to 10.6 years (mean 3.8 ± 2.2 years for patients and 5.5 ± 3.0 for carrier relatives).

RESULTS: Neurologic examination, neuropsychological testing, and daily living scores significantly declined in all patients with MELAS, whereas no significant deterioration occurred in carrier relatives. Cerebral MRI scores declined significantly in patients with MELAS. Magnetic resonance spectroscopy estimates of lactate in the lateral ventricles increased over time, and high lactate was associated with increased mortality. Symptom onset in childhood often was associated with worse outcome. Patients with MELAS had a greater death rate than carrier relatives.

CONCLUSIONS: Patients with MELAS carrying the m.3243A>G mutation show a measurable decline in clinical and imaging outcomes. It is hoped that these data will be helpful in anticipating the disease course and in planning clinical trials for MELAS.

DOI10.1212/WNL.0b013e31823a0c7f
Alternate JournalNeurology
PubMed ID22094475
PubMed Central IDPMC3235358
Grant List1-UL1-RR024156 / RR / NCRR NIH HHS / United States
P01-HD32062 / HD / NICHD NIH HHS / United States
Related Institute: 
MRI Research Institute (MRIRI)

Weill Cornell Medicine
Department of Radiology
525 East 68th Street New York, NY 10065